Emergent BioSolutions Inc. – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 15 PAGES: 126

More Info
									    Emergent BioSolutions Inc. – Product Pipeline Review – 2012

                                                                                          Reference Code: GMDHC02158CDB
                                                                                                 Publication Date: MAY 2012




Emergent BioSolutions Inc. – Product Pipeline Review – 2012                               GMDHC02158CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Emergent BioSolutions Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Emergent BioSolutions Inc. Snapshot ................................................................................................................................................ 8
    Emergent BioSolutions Inc. Overview ........................................................................................................................................... 8
    Key Information ............................................................................................................................................................................. 8
    Key Facts....................................................................................................................................................................................... 8
Emergent BioSolutions Inc. – Research and Development Overview ................................................................................................ 9
    Key Therapeutic Areas .................................................................................................................................................................. 9
Emergent BioSolutions Inc. – Pipeline Review ................................................................................................................................. 12
    Pipeline Products by Stage of Development ............................................................................................................................... 12
    Pipeline Products – Monotherapy ............................................................................................................................................... 13
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 14
Emergent BioSolutions Inc. – Pipeline Products Glance .................................................................................................................. 15
    Emergent BioSolutions Inc. – Late Stage Pipeline ...................................................................................................................... 15
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 15
    Emergent BioSolutions Inc. Clinical Stage Pipeline Products...................................................................................................... 16
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 16
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 17
    Emergent BioSolutions Inc. – Early Stage Pipeline Products ...................................................................................................... 18
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 18
Emergent BioSolutions Inc. – Drug Profiles...................................................................................................................................... 19
    A2M1 ........................................................................................................................................................................................... 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
    AH65 ........................................................................................................................................................................................... 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
    Anthrivig ...................................................................................................................................................................................... 21
        Product Description................................................................................................................................................................. 21
        Mechanism of Action ............................................................................................................................................................... 21
        R&D Progress ......................................................................................................................................................................... 21
    Anti-CD19 X Anti-CD-3 ................................................................................................................................................................ 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    Anti-CD86 X Mono-IL-10 ............................................................................................................................................................. 23
        Product Description................................................................................................................................................................. 23
        Mechanism of Action ............................................................................................................................................................... 23
        R&D Progress ......................................................................................................................................................................... 23



Emergent BioSolutions Inc. – Product Pipeline Review – 2012                                                                             GMDHC02158CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
Emergent BioSolutions Inc. – Product Pipeline Review




    Anti-HER2 X Anti-CD3 ................................................................................................................................................................. 24
        Product Description................................................................................................................................................................. 24
        Mechanism of Action ............................................................................................................................................................... 24
        R&D Progress ......................................................................................................................................................................... 24
    Anti-PSMA X Anti-CD-3 ............................................................................................................................................................... 25
        Product Description................................................................................................................................................................. 25
        Mechanism of Action ............................................................................................................................................................... 25
        R&D Progress ......................................................................................................................................................................... 25
    Anti-RON X Anti-CD3 .................................................................................................................................................................. 26
        Product Description................................................................................................................................................................. 26
        Mechanism of Action ............................................................................................................................................................... 26
        R&D Progress ......................................................................................................................................................................... 26
    CTLA-4 X mono-IL-10 ................................................................................................................................................................. 27
        Product Description................................................................................................................................................................. 27
        Mechanism of Action ............................................................................................................................................................... 27
        R&D Progress ......................................................................................................................................................................... 27
    ES301.......................................................................................................................................................................................... 28
        Product Description................................................................................................................................................................. 28
        Mechanism of Action ............................................................................................................................................................... 28
        R&D Progress ......................................................................................................................................................................... 28
    MVA85A ...................................................................................................................................................................................... 29
        Product Description................................................................................................................................................................. 29
        Mechanism of Action ............................................................................................................................................................... 29
        R&D Progress ......................................................................................................................................................................... 29
    NuThrax ....................................................................................................................................................................................... 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 32
    PreviThrax ................................................................................................................................................................................... 33
        Product Description................................................................................................................................................................. 33
        Mechanism of Action ............................................................................................................................................................... 33
        R&D Progress ......................................................................................................................................................................... 33
    Thravixa ....................................................................................................................................................................................... 35
        Product Description................................................................................................................................................................. 35
        Mechanism of Action ............................................................................................................................................................... 35
        R&D Progress ......................................................................................................................................................................... 35
    TNFR x A2 ................................................................................................................................................................................... 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    TNFR x TWEAKR ........................................................................................................................................................................ 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37


Emergent BioSolutions Inc. – Product Pipeline Review – 2012                                                                             GMDHC02158CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                       Page(3)
Emergent BioSolutions Inc. – Product Pipeline Review




    TRU-016 ...................................................................................................................................................................................... 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    TRU-016 + Bendamustine ........................................................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    Zanolimumab ............................................................................................................................................................................... 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
Emergent BioSolutions Inc. – Pipeline Analysis ............................................................................................................................... 42
    Emergent BioSolutions Inc. – Pipeline Products by Therapeutic Class ....................................................................................... 42
    Emergent BioSolutions Inc. – Pipeline Products By Target ......................................................................................................... 44
    Emergent BioSolutions Inc. – Pipeline Products by Route of Administration............................................................................... 46
    Emergent BioSolutions Inc. – Pipeline Products By Mechanism of Action .................................................................................. 47
Emergent BioSolutions Inc. – Recent Pipeline Updates .................................................................................................................. 49
Emergent BioSolutions Inc. - Dormant Projects ............................................................................................................................... 53
Emergent BioSolutions Inc. – Company Statement.......................................................................................................................... 55
Emergent BioSolutions Inc. – Locations And Subsidiaries ............................................................................................................... 60
    Head Office.................................................................................................................................................................................. 60
    Other Locations & Subsidiaries ................................................................................................................................................... 60
Emergent BioSolutions Inc., Recent Developments ......................................................................................................................... 63
    Emergent BioSolutions Inc.- Press Release ................................................................................................................................ 63
        Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate ......................... 63
        Dec 07, 2009: HHS Cancels RFP for rPA Procurement and Modifies Their Approach in Favor of BAA for Development of rPA
        Vaccines ................................................................................................................................................................................. 64
        Nov 12, 2009: Trubion Announces Acceptance Of Two Presentations On Its TRU-016 Product Candidate At The 2009 ASH
        Annual Meeting ....
								
To top